Victor Weigman, PhD Q2 Solutions, a Quintiles Quest Joint Venture
Victor Weigman, PhD Q2 Solutions, a Quintiles Quest Joint Venture
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of cancer using both DNA and RNA approaches including the development and deployment of robust assays that can be leveraged clinically as laboratory developed tests.
Dr. Weigman brings more than 13 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays and facilitation of genomics based Companion Diagnostics.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center under the supervision of Charles Perou.